Anika Therapeutics, Inc. Operating Income Loss

• Anika Therapeutics, Inc. showed a decrease of -116.6% in Operating Income Loss from 2024 to 2025.
• This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Anika Therapeutics, Inc.'s Operating Income Loss has declined by 297.8%.
• Historical annual values: Fiscal year 2025: -$11.05 million | Fiscal year 2024: -$5.10 million | Fiscal year 2023: $844.0 thousand | Fiscal year 2022: $3.67 million | Fiscal year 2021: $2.62 million | Fiscal year 2020: -$28.32 million | Fiscal year 2019: $34.25 million | Fiscal year 2018: $21.75 million | Fiscal year 2017: $45.73 million | Fiscal year 2016: $50.61 million | Fiscal year 2015: $48.13 million | Fiscal year 2014: $61.45 million | Fiscal year 2013: $32.61 million | Fiscal year 2012: $19.72 million | Fiscal year 2011: $13.97 million | Fiscal year 2010: $7.54 million | Fiscal year 2009: $5.59 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026